https://dmoginhibitor.com/benc....hmarking-monolayer-m
Four-year total survival (OS) ended up being 95.4% and 4-year progression-free survival (PFS) had been 84.5%. The relationship between localization and relapse was considerable in 197 patients with stage 2 and phase 3 (p=0.003). In this client team, 41 (20.8%) relapses had been observed. Thirty (73.2%) for the relapses were within the correct testis and 11 (26.8%) into the left testis. Four-year OS had been 92.1% in patients with correct tumor; and 98.7% in patients with remaining tumor (p=0.
Like
Comment
Share
